Activated Charcoal Alfalfa Antimony Trisulfide Ave

證據等級: L5

預測適應症: 0 個

Multi-Component Compound (22 Ingredients): No Repurposing Prediction Available

One-Sentence Summary

This formulation is a 22-ingredient combination of digestive enzymes, bitter botanicals, and traditional herbal/homeopathic components—including pancrelipase, pepsin, gentian, licorice, cascara, and nux vomica—with no registered original indication on record. The TxGNN model was unable to generate a repurposing prediction because the compound lacks a DrugBank ID and cannot be anchored in the knowledge graph. No clinical trial or literature evidence is currently linked to this formulation as a unified entity.

Quick Overview

Item	Content
Original Indication	Unknown (no registration found)
Predicted New Indication	None — model could not process
TxGNN Prediction Score	N/A
Evidence Level	Not Evaluable
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN repurposing prediction was generated for this compound. The TxGNN pipeline requires a DrugBank ID to locate a drug node within the knowledge graph and compute disease associations. Since this multi-component formulation has no DrugBank ID, the model cannot link it to any disease node, making score computation impossible.

Based on its ingredient profile, this appears to be a traditional gastrointestinal/hepatobiliary compound, likely of homeopathic or phytotherapeutic origin. Several components are hallmarks of classical homeopathic preparations: Strychnos nux-vomica seed (nux vomica), Lycopodium clavatum spore, Carbo Animalis (animal charcoal), Chelidonium Majus, and Berberis Vulgaris are all listed in the Homeopathic Pharmacopoeia of the United States (HPUS). The concurrent presence of pancrelipase, pepsin, and ox bile (Bos taurus bile) suggests a digestive enzyme supplement function, while gentian root, cascara (Frangula purshiana bark), star anise, and licorice are conventional bitter tonics and carminatives. Indole and skatole—volatile intestinal fermentation byproducts—also appear in homeopathic bowel preparations.

To enable a formal TxGNN repurposing analysis, the compound would need to be decomposed into individual ingredients for separate evaluation, or alternatively, a lead active component (e.g., berberine from Berberis vulgaris, or glycyrrhizin from Glycyrrhiza glabra) would need to be designated as the primary entity.

Clinical Trial Evidence

Currently no related clinical trials registered for this multi-component formulation as a unified entity.

Literature Evidence

Currently no related literature available for this exact multi-component formulation.

Safety Considerations

Please refer to the package insert for safety information.

Note on Nux Vomica: Strychnos nux-vomica seed contains strychnine, which is toxic at non-homeopathic doses. If this is a conventional (non-homeopathic) formulation, the concentration of nux vomica extract should be verified against safe upper limits before any clinical use evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline cannot evaluate this compound in its current form. Without a DrugBank ID, an original indication, or any predicted indication, there is no basis for a repurposing evaluation.

To proceed, the following is needed:

Clarify regulatory classification: Determine whether this is a homeopathic preparation (HPUS-listed), a phytotherapeutic combination, or a conventional OTC digestive enzyme supplement — each follows a different regulatory and evidence pathway
Assign a DrugBank ID or decompose into individual ingredients: Evaluate each of the 22 active components separately through TxGNN; leading candidates (berberine, glycyrrhizin, pancrelipase, pepsin) already have DrugBank entries
Identify the original registered indication: Even an informal use case (e.g., dyspepsia, digestive insufficiency, liver support) is needed to anchor the repurposing analysis
Obtain complete safety data: Retrieve the full package insert to document warnings, contraindications, and dosing limits — especially regarding nux vomica (strychnine content) and antimony trisulfide
Confirm US market status: A TFDA query returned 0 results and DDI lookup was not found; an independent US FDA Orange Book search should confirm whether any NDA or ANDA exists under a brand name
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.